FindTrial
Sign In

Clinical study on the efficacy and safety of extracorporeal blood oxygenation and ozonation in ischemic cardiovascular patients - EBOO in cardiologt

Clinical study on the efficacy and safety of extracorporeal blood oxygenation and ozonation in ischemic cardiovascular patients - EBOO in cardiologt

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2006-001547-59-IT
Enrollment
Unknown
Registered
2007-04-18
Start date
2006-03-01
Completion date
Unknown
Last updated
2014-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient with ischemic cardiopaty Level: HLT Classification code 10011085

Interventions

Trade Name: TORVAST 20 10CPR 20MG Pharmaceutical Form: Film-coated tablet INN or Proposed INN: Atorvastatin CAS Number: 134523-03-8 Concentration unit: mg milligram(s) Concentration type: equal Concen

Sponsors

AZIENDA OSPEDALIERA SENESE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Ischemic cardiopatic patients selected for surgery Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Acute ischemic syndrome 30 days before the study inclusion. Severe other cardiopaties. Diabetic patients

Design outcomes

Primary

MeasureTime frame
Main Objective: Evaluation of the effects of EBOO therapy in patients with ischemic cardiopaty;Secondary Objective: None;Primary end point(s): Improvement of the heart ischemia—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026